Jasper Therapeutics Completes IgAN Cohort Enrollment
The company completed enrollment in the IgA nephropathy cohort of its Phase 2 vensobafusp alfa basket study and expects initial data by year-end 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.